News Search Results
May 19, 2025, 14:08 ET Regenics AS appoints Jostein Grip as new CEO
Norway, May 19, 2025 /PRNewswire/ -- Regenics AS, a private Norwegian biotechnology company based in Oslo, today announced that it has appointed Jostein Grip as the
More news about: Regenics AS
May 19, 2025, 13:04 ET Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
May 19, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
May 19, 2025, 10:30 ET eCOA Solutions Market worth US$4.78 billion by 2030 with 16.1% CAGR | MarketsandMarkets™
for the largest share of the Electronic Clinical Outcome Assessment (eCOA) Solutions market. This region is home to numerous pharmaceutical and biotechnology companies that utilize electronic Clinical Outcome Assessment (eCOA) solutions. These companies conduct extensive clinical trials, aiming for efficient
More news about: MarketsandMarkets
May 19, 2025, 10:22 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
![Synoligo Biotechnologies and Lumiphore Announce a Partnership to Provide [Time-Resolved] Luminescent Oligos and Assays for the Nucleic Acid Amplification Testing Market (NAAT)](https://mma.prnewswire.com/media/2690006/Main_2024_Final_Version_Logo.jpg?w=300){kind=logo}
May 19, 2025, 10:08 ET Synoligo Biotechnologies and Lumiphore Announce a Partnership to Provide [Time-Resolved] Luminescent Oligos and Assays for the Nucleic Acid Amplification Testing Market (NAAT)
therapeutic applications. About Lumiphore, Inc. Based in Berkeley, California, Lumiphore Inc., is a biotechnology leader in the development of proprietary luminescent lanthanide reporters and radionuclide payload delivery technology, for use in high-value diagnostics
More news about: Synoligo Biotechnologies Inc.
May 19, 2025, 10:01 ET Sterile Filtration Market is expected to generate a revenue of USD 20.76 Billion by 2031, Globally, at 11.30% CAGR: Verified Market Research®
The sterile filtration market is witnessing steady growth driven by its critical role in pharmaceutical, food & beverage, and biotechnology sectors to ensure contamination-free production processes. Key Highlights of the Report: Market Size &
More news about: Verified Market Research
May 19, 2025, 10:00 ET J.P. Morgan Life Sciences Private Capital Welcomes Dashyant Dhanak, Ph.D. as Venture Partner
healthcare companies. The early stage biotechnology practice is focused on company creation, Seed and Series A investments across all therapeutic areas in biotechnology. The late-stage healthcare practice is focused on Series B through pre-IPO investments within biotechnology, medical devices, tools, diagnostics,
More news about: J.P. Morgan Asset Management
May 19, 2025, 08:00 ET Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today released a letter to shareholders from Chairman and CEO Dr. Amit
More news about: Anixa Biosciences, Inc.
May 19, 2025, 07:00 ET Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
May 19, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
May 17, 2025, 09:48 ET SANA Deadline: SANA Investors with Losses in Excess of $100K Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive
More news about: THE ROSEN LAW FIRM, P. A.
May 16, 2025, 16:01 ET AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
May 16, 2025, 14:11 ET Fzata Announces the Appointment of A New Board Member
clients in the life sciences for over 30 years, providing IP and transactional services. She was named to The Best Lawyers in America list for Biotechnology and Life Sciences, 2016 to 2023, as well as Chambers USA "America's Leading Lawyers in Intellectual Property" list
More news about: Fzata, Inc.
May 16, 2025, 13:29 ET 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
us on Facebook, Twitter, Instagram and Snapchat (Society4Science). About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists,
More news about: Society for Science
May 16, 2025, 11:30 ET Live Cell Imaging Market Skyrockets to $4.49 billion by 2030 Dominated by Healthcare Giants - Carl Zeiss, GE HealthCare, PerkinElmer, Leica Microsystems | Exclusive Report by The Research Insights
a dynamic field in recent years with prospects for substantial growth because of increasing demand for superior imaging technologies. Prominent biotechnology and pharmaceutical companies in the region drive this trend while establishing an environment rich in innovation and investment opportunities. The
More news about: The Research Insights
May 16, 2025, 11:10 ET SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment
its global R&D and licensing footprint in nucleic acid and antibody therapeutics, and is committed to becoming a globally impactful leader in biotechnology innovation. About Microbio (Shanghai) Co., Ltd.Microbio (Shanghai),
More news about: Oneness Biotech; Microbio (Shanghai)
May 16, 2025, 10:30 ET Laboratory Information Management System Market worth US$5.19 billion by 2030 with 12.5% CAGR | MarketsandMarkets™
US$5.19 billion by 2030. The adoption of cloud-based LIMS is driven by the growing volume of laboratory data, growing pharmaceutical & biotechnology R&D expenditure, and the reduced total cost of ownership for informatics solutions. Factors such as automation, improved data accuracy, regulatory
More news about: MarketsandMarkets
May 16, 2025, 10:07 ET Fzata to Attend BIO International Convention 2025
Md., May 16, 2025 /PRNewswire/ -- Fzata, Inc., a near clinical-stage biotechnology company developing oral biologics for GI disorders, announces it will attend the BIO International Convention 2025 in Boston.
More news about: Fzata, Inc.
May 16, 2025, 07:30 ET BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Conference ID: 2239224 About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
May 16, 2025, 06:24 ET Haier Consolidates Its Position as One of the Most Valuable Global Brands and the Only IoT Ecosystem Brand in the World
home ecosystem brand. In Comprehensive Health, Haier has formed a full-spectrum health ecosystem spanning life science, clinical medicine, and biotechnology. With rapid expansion over the past five years, its healthcare business has become a national industry leader. Also, Haier's Digital Economy Ecosystem,
More news about: Haier Group
May 16, 2025, 06:04 ET Haier Consolidates Its Position as One of the Most Valuable Global Brands and the Only IoT Ecosystem Brand in the World
home ecosystem brand. In Comprehensive Health, Haier has formed a full-spectrum health ecosystem spanning life science, clinical medicine, and biotechnology. With rapid expansion over the past five years, its healthcare business has become a national industry leader. Also, Haier's Digital Economy Ecosystem,
More news about: Haier Group
May 16, 2025, 05:45 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
May 16, 2025, 04:00 ET Genome & Company's Skincare Brand UIQ Expands into North America with Official Amazon Brand Store Launch
Korea, May 16, 2025 /PRNewswire/ -- Genome & Company, a global clinical-stage biotechnology firm, has officially launched its skincare brand UIQ (www.theuiq.com) on Amazon,
More news about: Genome & Company
May 16, 2025, 04:00 ET Genome & Company's Skincare Brand UIQ Expands into North America with Official Amazon Brand Store Launch
Korea, May 16, 2025 /PRNewswire/ -- Genome & Company, a global clinical-stage biotechnology firm, has officially launched its skincare brand UIQ (www.theuiq.com) on Amazon,
More news about: Genome & Company
May 15, 2025, 21:00 ET ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information about the company, please visit our website:
More news about: Arkbio
May 15, 2025, 21:00 ET ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information about the company, please visit our website:
More news about: Arkbio